Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
about
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trialAn inter-platform repeatability study investigating real-time amplification of plasmid DNACurrent Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaMolecular Detection of Foodborne Pathogens: A Rapid and Accurate Answer to Food Safety.All-in-one processing of heterogeneous human cell grafts for gene and cell therapy.Vy-PER: eliminating false positive detection of virus integration events in next generation sequencing data.Endothelial progenitor cells display clonal restriction in multiple myeloma.Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia.Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience.Prognostic value of deep sequencing method for minimal residual disease detection in multiple myelomaScreening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis.The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective StudyDevelopment of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet.Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy.Flow cytometry and polymerase chain reaction-based analyses of minimal residual disease in chronic lymphocytic leukemia.Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testingGenomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid LeukemiaA certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCRMicrofluidic channel-assisted screening of hematopoietic malignancies.Development of one-step SYBR Green real-time RT-PCR for quantifying bovine viral diarrhea virus type-1 and its comparison with conventional RT-PCR.Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?A further milestone towards comprehensive standardization of quantitative RT-PCR protocols for leukemic fusion gene transcripts has been reached.Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid eraMolecular monitoring of minimal residual disease in patients with multiple myeloma.A novel approach for determining cancer genomic breakpoints in the presence of normal DNAImproved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction.Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation.Development and use of biomarkers in oncology drug development.Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.How and when should we monitor chimerism after allogeneic stem cell transplantation?Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.Detection and Identification of Hematologic Malignancies and Solid Tumors by an Electrochemical Technique.Basic principles of real-time quantitative PCR.Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansionMolecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse.Measurements of treatment response in childhood acute leukemia.
P2860
Q24621523-93686E74-E1A4-4240-9126-0327074EA98EQ24815055-299C7E36-C808-47B3-9DBC-1A7791DA4433Q26751269-9A09E025-B379-4E11-8CE3-2112A0AF4918Q30252167-D7FD096D-DE1D-4325-8DA5-B6104C176614Q30387995-2F2773FB-9424-43CE-BBF7-198E682C6AD1Q30979834-695654B4-A416-4310-8260-4B6D3958A56FQ33247497-16BE4C54-2EDD-4FFC-B321-2282335B0E40Q33524890-E6588F73-9790-448B-B4F3-11155EA12EF6Q33588450-44DFF59F-88B9-488F-89AD-F7D4FDCB153FQ33621587-4407AD69-1D51-46D8-95A9-5F87A53B1E36Q33829070-4965BFF2-55BC-4CA6-8BD5-CF9C8F209F0FQ33849498-F8A572DE-C64E-49DD-B22B-AA1456CC89BAQ33873297-87F65D4E-AFD4-4444-9B84-C823A2C713DEQ33886177-06BD5C88-D42B-49E2-BEA4-FB330D6A30D1Q33997798-50A86C98-2059-46D6-AD5E-48F68A0CB42DQ34155701-AD6A6E3A-0806-420C-9DB5-E63D7996E8B5Q34425875-604969FC-03B5-47F1-AF7D-8E5953BC37DAQ34781322-06D92218-77D5-496A-87CE-4013516C406BQ35059443-F6FBA4D6-1561-4D93-99CF-320832631B62Q35067051-E5705E42-FF62-433B-A4B7-752BDA20F9E9Q35168737-39D12B36-1DDA-4932-9FD7-B75A5E91E883Q35203844-B9C4390D-1EBB-4DD9-A881-07CEFF0B4312Q35561034-08C45B6D-85B1-4D51-902C-4D4CE427046AQ35561038-2E3361F7-77F6-42D5-8E50-8BFB1D609864Q35640734-BF083DDB-F8CE-40E2-BB1B-4304B1D73DEAQ35668677-116B8A51-B0D8-447A-B8F8-A01ABD60B6B9Q35741860-B27BBD2F-8374-481C-A1BD-589B0317840BQ35757696-7EC42CF2-8B61-410B-ADAB-798B7CA8EE5AQ35790075-0839940F-9594-4BC9-8DE7-47D71812D4F2Q35792825-4A4B88C1-7175-4CBB-9B1F-6DBE52E7FB1BQ35812532-E1F11E1E-CB65-42BB-AB72-875C135260ACQ35816396-80B8409A-D047-43CE-9EA2-B3D3EA61DE9AQ35849776-B11E3830-9F31-40CD-A477-41188B088682Q35926907-239E0CBD-89C2-4C28-BC14-254E4904B275Q35976588-668721BE-BBF0-4CEC-889E-195ED34C45F7Q35999322-F3ACE6ED-91B8-41A8-A037-F1B52DF9CFE0Q36099379-7CD5642E-3DA8-4FF7-BCD7-B7A33E35E7ABQ36267196-B3782237-C310-4A4D-8F26-FF670877832AQ36444440-2A53B6E1-902B-437B-805A-8B29394F91BAQ36513773-7E9C2C9F-D7B8-437B-9119-0C87C3995E57
P2860
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Detection of minimal residual ...... aches, and laboratory aspects.
@ast
Detection of minimal residual ...... aches, and laboratory aspects.
@en
type
label
Detection of minimal residual ...... aches, and laboratory aspects.
@ast
Detection of minimal residual ...... aches, and laboratory aspects.
@en
prefLabel
Detection of minimal residual ...... aches, and laboratory aspects.
@ast
Detection of minimal residual ...... aches, and laboratory aspects.
@en
P2093
P2860
P50
P356
P1433
P1476
Detection of minimal residual ...... oaches, and laboratory aspects
@en
P2093
Cazzaniga G
van der Velden VH
P2860
P2888
P304
P356
10.1038/SJ.LEU.2402922
P577
2003-06-01T00:00:00Z